Member Info for nursesteve

When it went all negative this morning I expected the usual poor price action to a positive RNS so I put a small limit buy order in to top up - very pleasantly surprised to see it’s very unlikely to go through GLALTH’s

Seems to be ✅ my up nicely

AVACTA proving the platform by targeting 4 different cancers with this latest payload ✅

Was the “A” the start of a Philly type chant ? Give me an A give me a V …(AVACTA!)

Aldebaran had previously said his first language isn’t English.

I’ve found his contributions to be better than a lot of others who simply abuse fellow posters here

Maybe the talks went well? What’s not to like in that presentation ?

More than half the usual daily volume traded already and the share price is up 10%. Not just me buying then. Could it possibly be some institutional investors are buying in ahead of meeting AVACTA on Tuesday? Even possible that we could see a TR1 at long last? 🤔

I’m now part of the early buying as I’ve added a few more with a small top up of 1479 shares. GLA

Some nice early buys going through

Worth noting the payload of these drugs only get cleaved by a tumor-specific protease (fibroblast activation protein or FAP) so they are designed to concentrate highly potent payloads in the tumor microenvironment - sparing normal tissues. Since safety has been proven also approved by the FDA for no maximum dose now. Efficacy is the next skittle to go and animal trials indicate superb potential efficacy as does AI modelling for the trial that has been scheduled to start in this years first quarter. Has the first patients and been dosed yet? From memory I don’t think they RNSed first patients being dosed before 🤔 if there’s signs of initial efficacy (very likely with the reported one log higher data) would they be able to indicate this to potential investors they are due to meet on Tuesday?

I should add they’ve not only been put on notice but they’ve been invited for a sit down chat on 3rd March - see previous RNS

- so definitely not too long to wait.

It might take a little longer than the first 1/4 but the first half of this year is certainly showing increasing potential to be (at long last) truly transformative!

We won’t have long to wait till we find out if the AI results are replicated. Clinical trial with AVA6103 is expected to be initiated in Q1 2026. Almost into March … times ticking and big Pharma have been put on notice! GLALTH’s

CJ62 nice summary. Dragons Den indeed. The presentation at 9:10 am followed up with investor meetings throughout the day.

As Hurst quoted Chris earlier " We continue to have multiple conversations with global pharmaceutical companies regarding our full pipeline. We are incredibly excited for the year ahead, which the board believes will be a transformative period for the Company, patients and our shareholders."

The primary purposes of the Conference’s focused sessions include:

Facilitating Relationship Building: These meetings allow executive leadership teams—typically CEOs and CFOs—to establish personal rapport and trust with existing and potential shareholders.

Conducting Detailed Due Diligence: The intimate format enables investors to obtain specific, granular information necessary to complete comprehensive research and make informed investment decisions.

Clarifying Strategy and Progress: Investors use this time to ask technical or nuanced questions about a company's clinical progress, market opportunities, and long-term growth objectives that may not be addressed in a 20-minute fireside chat.

Direct Interaction with Management: They provide a rare opportunity for investors to assess the competence and vision of the leadership team firsthand in a non-public setting.

Efficiency for Multi-Stage Companies: For both public and private companies, these meetings are a streamlined way to meet with many targeted investors in a short period to discuss private deals or investment opportunities.

GLA

A lot of people (inc big pharma) sitting on their hands just now. Volume is down but that can very soon change. GLA

It seems a bit strange from Simon being touted by Chris as being so busy to quietly being removed ?

So Simon was busy doing??? 🤔

In the recently released investor meet Q&A answers ( to Q5 & Q8 ) the last 30 seconds of each answer describe talks of partnership for a different drug other than AVA6000 or AVA6103. So I wouldn’t be too surprised to see an RNS on this soon. As Simon and the business development team are involved that may take care of the funding for these two assets enabling them to stay in house? https://www.investormeetcompany.com/meetings/interim-results-491

Strong hold! Buy if you have spare cash! We are on our way up (back to the 80’s in the short term. In the medium term much much higher!). GLALTH’s

Removing the dosing limit also increases the potential value of the market for this drug. = More drug can be sold so more profit to be made!